Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. - Wikidata - wikimedia - TriplyDB

Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.

Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.

http://www.wikidata.org/entity/Q44314565

about

Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis Assessing the impact of heart failure specialist services on patient populations Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis Surgical ventricular restoration to reverse left ventricular remodeling.Current and emerging antiarrhythmic drug therapy for ventricular tachycardia Patterns of beta-blocker intensification in ambulatory heart failure patients and short-term association with hospitalization.Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers Peri-operative beta-blockade and haemodynamic optimisation in patients with coronary artery disease and decreasing exercise capacity presenting for major noncardiac surgery.The implications of physical activity in patients with chronic heart failure.Cardiac Effects of Attenuating Gsα - Dependent Signaling Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET.Effectiveness of beta-blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age?Hypertension and heart failure: role of neurohormonal mechanisms.Early initiation of beta blockade in heart failure: issues and evidence.The current prevalence of sleep disordered breathing in congestive heart failure patients treated with beta-blockers.The role of adrenergic receptor polymorphisms in heart failure.Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol.Beta-blocker therapy of heart failure: an update.Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5.Carvedilol in the treatment of elderly patients with chronic heart failure.Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction.Do general practitioners follow treatment recommendations from guidelines in their decisions on heart failure management? A cross-sectional study Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information.Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score.Prognosis and natural history of drug-related bradycardia.Role of carvedilol controlled-release in cardiovascular disease.Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure.Efficacy of Intravenous Administration of Landiolol in Patients With Acute Heart Failure and Supraventricular Tachyarrhythmia.β-blockers and their mortality benefits: underprescribed in heart failure and chronic obstructive pulmonary disease.Myocardial regeneration in heart failure: integrated development of biological therapeutic approaches.Non-withdrawal of beta blockers in acute decompensated chronic and de novo heart failure with reduced ejection fraction in a prospective multicentre study of patients with acute heart failure in the Middle East.The patient with left ventricular systolic dysfunction now and in the future.Carvedilol in chronic heart failure: past, present and future.Resynchronization therapy is an important advance in the management of congestive heart failure: view of an antagonist.[Heart failure update 2010 and current ESC guidelines].Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison.Impact of beta-2 Thr164Ile and combined beta-adrenergic receptor polymorphisms on prognosis in a cohort of heart failure outpatients.An appropriate indication for the initiation of beta-blocker therapy in dilated cardiomyopathy.Carvedilol case history: the discovery and development of the first β-blocker for the treatment of congestive heart failure.

P2860

Q21132299-2A127078-4BB1-4918-A5AA-E72F8AF5AB73 Q24796348-800434FE-8CAF-4E09-A630-E945B5035110 Q30239022-D6F507AF-B611-4EBD-8BC0-47BF5BDEEFD7 Q33754169-EFF1D1AE-07BB-4DF2-A62F-590A5D68BB2A Q33936131-D6E9B332-B7F4-4F27-9D41-ABA3326DBFAD Q34307931-F3EC2E3D-8B13-42D0-AF96-4B4C48D2E7B9 Q35110915-35F37C6F-40F5-46E1-A675-7FC5A8127C4F Q35612101-AD4F783A-B8E5-48C4-B3ED-E3843A871264 Q35660774-9B06F898-32D9-48A3-84AE-D88D757D8CDC Q35904773-E08BD668-0453-4D5B-8855-0DD3FC3F961C Q35985739-5BAD5F5B-0018-4510-B1A5-D886B805BBC8 Q36025044-BE7AD35D-53D0-47E4-9561-B04AEF505484 Q36035785-5ACF38D5-856E-4939-80C8-7987F6FDAAC3 Q36287752-AAF02AB4-14D2-4DEE-9293-1958293D648D Q36513398-FE3DAD24-671B-4AA8-9B1A-3803952B546B Q36629879-AD68259B-E98B-4308-A0F9-498B843CC1E2 Q36675404-8552853C-372A-431F-B699-689CEFFCE369 Q36723828-311E1213-353A-4A92-91DB-C584AECC4FD4 Q36848480-16A8B86A-B838-4F3E-874D-9FB15717A960 Q36892905-A0E7153B-7E2C-4694-9C89-167760F94CE3 Q36961345-A58A45D1-402F-49DA-B4D0-DEE649C3E852 Q37190371-AA786DAE-2CA7-406B-B8FC-FFF1B0CB06B1 Q37285522-3BAA0C2B-7D22-426B-B43A-FA605325F6A8 Q37328512-D6C72287-DE68-44D2-B9C1-CBF9466DF05B Q37408756-2AE07820-27B2-4D5C-A9DC-8B211267ADAD Q37472042-98A5C388-90DE-42A9-A811-C1596D38D15E Q37588012-647D2E2D-6F8E-481F-8B2C-12987D9C53BA Q37737193-0F7A3F42-B41D-4DEB-8511-97A33179D90E Q37822723-93E8AE16-B36E-4C88-B06B-6D32DC694289 Q37923971-C98E021B-A309-4840-B873-66D97053D129 Q38685401-63CD004D-2C4C-4772-9B62-3ED5AEFA801E Q38820073-637CE4B5-10F8-4FD7-AA54-FDA9B87EEEA6 Q40377169-9A17EBBA-0558-441E-9713-1F3087D7DD4E Q40564909-B7A6069A-4F40-4F89-8AE2-0B2C5340D728 Q42835997-90357123-0661-48A5-A184-79CB3E6EBE90 Q44925682-63961A0D-16D9-4268-940E-AA73CB93EFB4 Q45034589-E0A35A4E-FF7B-4AEF-A237-B3FCDEE90600 Q46046251-04D219E0-29E4-416A-9866-AABCFBFA4D53 Q46792937-5AB49737-ECDC-48AA-A24C-5301DD705C85 Q47595649-46D4DB1D-C4DE-41A3-A2BF-4493F091681B

P2860

Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.

http://www.wikidata.org/entity/Q44314565

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Effects of initiating carvedil ...... lts from the COPERNICUS Study.

@en

Effects of initiating carvedil ...... lts from the COPERNICUS Study.

@nl

type

label

Effects of initiating carvedil ...... lts from the COPERNICUS Study.

@en

Effects of initiating carvedil ...... lts from the COPERNICUS Study.

@nl

prefLabel

Effects of initiating carvedil ...... lts from the COPERNICUS Study.

@en

Effects of initiating carvedil ...... lts from the COPERNICUS Study.

@nl

P1433

Q44314565-E0E370AA-10BA-4920-AAEC-CAC355384EC0

P1476

Q44314565-807A34B0-A5BF-4034-82B8-B576C169B961

P2093

Q44314565-2EC3D094-02B6-4AB9-8391-6B728E1C75D7

Q44314565-331602B0-329B-47B8-91B3-C4F3B7FF3500

Q44314565-5B3C0BA8-70CC-4374-A367-E4A376362FB0

Q44314565-6F33354E-74FB-4A88-AF0A-5FB40AB00F9E

Q44314565-733718E7-E377-4BD8-A531-E11DB119C470

Q44314565-9CBF72B5-DD74-4D55-BD62-633F184C6CA4

Q44314565-BF19129B-1735-43EB-A073-E225B385554F

Q44314565-C6B0BCD6-9D9F-48B0-913B-4C146C55D31E

P304

Q44314565-A8BB5F3E-EA67-47A9-8FF6-2C8DDBE52D1E

P31

Q44314565-8601109E-3E5D-45E2-8E3C-B2FA03153EF0

P356

Q44314565-CA0BCA07-1BF3-44BC-8383-33F5858FC62C

P407

Q44314565-BC39CA2B-CF8A-4016-AD43-D6C447FD15FD

P433

Q44314565-AAA954C7-3223-4FDF-8750-1408E6853836

P478

Q44314565-95ACA10B-570B-4832-8EFA-021B44B0FE6E

P50

Q44314565-55988296-8D52-4C7C-9135-748319F1FDE3

Q44314565-703303B6-A5F5-49C7-AFC0-4733E20E0DD0

P577

Q44314565-06E54AB7-A015-4260-92E9-0FB06C86FE70

P5875

Q44314565-BE872504-F23A-4E9C-A4AB-37A4A1042BB3

P698

Q44314565-498B39AE-8097-4A97-99EA-BC100C468878

P921

Q44314565-DF412E04-BE81-48BA-957F-41CFA30CA7D1

Q44314565-E18DA5B7-E6E8-431B-9A98-03723F845D0A

P356

P1433

Journal of the American Medical Association

P1476

Effects of initiating carvedil ...... lts from the COPERNICUS Study.

@en

P2093

Andrew J S Coats

http://www.w3.org/2001/XMLSchema#string

Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group

http://www.w3.org/2001/XMLSchema#string

Ellen B Roecker

http://www.w3.org/2001/XMLSchema#string

Hugo A Katus

http://www.w3.org/2001/XMLSchema#string

Jean L Rouleau

http://www.w3.org/2001/XMLSchema#string

Michael B Fowler

http://www.w3.org/2001/XMLSchema#string

Milton Packer

http://www.w3.org/2001/XMLSchema#string

Paul Mohacsi

http://www.w3.org/2001/XMLSchema#string

P304

712-718

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.289.6.712

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

289

http://www.w3.org/2001/XMLSchema#string

P50

Michał Tendera

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10901008

http://www.w3.org/2001/XMLSchema#string

P698

12585949

http://www.w3.org/2001/XMLSchema#string

P921